Kiran Mazumdar Shaw

Bio-Data
Born: March 23, 1953 Residence : Bangalore QUALIFICATIONS

schooling : Bishop Cotton Girls High School BSc Zoology Honors course from Bangalore University Post-graduation in Malting and Brewing from Ballarat College, Melbourne University Chairman & Managing Director of Biocon Limited. Chairperson of Syngene International Limited and Clinigene International Limited.

BIOCON
Started Biocon in 1978

Fully integrated bio-pharmaceutical company with

a well-balanced business portfolio of products and a research focus on diabetes, oncology and auto-immune diseases. 2 subsidiaries: Syngene (1994) to provide development support services for discovery research and Clinigene (2000) to cater to clinical development services

JOURNEY
1978,

Joined Biocon Biochemicals Limited, of Cork, Ireland as a Trainee Manager. In the same year she started Biocon in the garage of her rented house in Bangalore with a seed capital of Rs. 10,000. 1989 Biocon became the first Indian company to manufacture and export enzymes to USA and Europe.

Cont.
1990,

Upgraded Biocons in-house research program, based on a proprietary solid substrate fermentation technology. 1996 commercial success of this program led to a three-fold expansion 1997 Undertook initiatives in human healthcare through a dedicated manufacturing facility

Cont.
1998

when Unilever agreed to sell its shareholding in Biocon to the Indian promoters, Biocon became an independent entity. 2000 Biocon's proprietary bioreactor, christened PlafractorTM, based on solid matrix fermentation received a U.S. patent and Kiran MazumdarShaw commissioned Biocons first fully automated submerged fermentation plant to produce specialty pharmaceuticals.

Cont.
2003

Biocon became the first company worldwide to develop human insulin on a Pichia express system. 2004 Access the capital markets to develop Biocons pipeline of research programs. Biocons IPO was oversubscribed 32 times and its first day at the bourses closed with a market value of $1.11 billion, making Biocon only the second Indian company to cross the $1-billion mark on the first day of listing

Cont.
Between 2005 and 2010

She entered into more than 2,200 high-value R&D licensing and other deals within the pharmaceuticals and bio-pharmaceutical space and helped Biocon expand its global footprint to emerging and developed markets through acquisitions, partnerships and in-licensing.

Cont.
2007-08

LeadingUS trade publication, Med Ad News, ranked Biocon as the 20th leading biotechnology companies in the world and the 7th largest biotech employer in the world 2009 Received BioSingapore Asia Pacific Biotechnology Award for Best Listed Company It has Asias largest insulin and statin facilities as also the largest perfusion-based antibody production facilities.

Philanthropic activities
In 2004, she started the Biocon Foundation to

conduct health, education, sanitation, and environment programs for the benefit of the economically weaker sections of society. The Foundations micro-health insurance program has an enrolment of 70,000 rural members She helped establish a 1,400-bed cancer care center at the Narayana Health City campus at Boommasandra, Bangalore, Mazumdar Shaw Cancer Centre (MSCC)

Awards
Veuve Clicquot Initiative For Economic Development

For Asia (2002) Ernst & Young's Entrepreneur of the Year Award for Life Sciences & Healthcare (2002) Corporate Leadership Award by the American India Foundation (2005) Nikkei Asia Prize (2009) for Regional Growth, Express Pharmaceutical Leadership Summit Award (2009) for Dynamic Entrepreneur Awarded honorary doctorates from University of Abertay, Dundee, UK (2007), University of Glasgow, UK (2008) Heriot-Watt University, Edinburgh, UK (2008).

QUOTES
Success is about pursuing a vision with a sense

of purpose and a spirit of challenge. There are no short cuts to success and there is no substitute for hard work. I also believe success is about doing things in a differentiated way - dare to be different so that you stand out. Biocon's byline is The difference lies in our DNA and we all believe in it. We don't imitate other companies but have charted our own business destiny.